|
Patient No. |
Age (y) |
Lesion
No.*
|
Core Biopsy Date |
MR Imaging Diagnosis
|
Core Histologic Finding |
Type of Validation |
Validation Accepted
|
|
|
Patients with lesions rated as
"probably benign" |
|
1 |
43 |
1 |
03/98 |
FD |
FD |
MR imaging follow-up (27 mo) |
Yes (b) |
|
2 |
57 |
2 |
06/00 |
FD |
FD with adenosis |
R/P correlation |
No |
| |
|
3 |
06/00 |
FD |
FD with adenosis |
R/P correlation |
No |
|
3 |
33 |
4 |
01/00 |
FD |
FD with lobular hyperplasia, no
atypias |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
4 |
22 |
5 |
04/00 |
FA |
Typical FA |
R/P correlation |
Yes (c) |
|
5 |
44 |
6 |
04/98 |
FD |
FD with adenosis |
R/P correlation; MR imaging follow-up (24
mo); mastectomy in 5/00: adenosis, no atypias |
Yes (a) |
|
6 |
64 |
7 |
09/98 |
FA |
Typical FA |
R/P correlation; MR imaging follow-up (24 mo) |
Yes (b) |
|
7 |
54 |
8 |
03/00 |
FA |
Typical FA plus LCIS within FA |
R/P correlation; excisional biopsy in 4/00;
MR follow-up (6 mo) |
Yes (a) |
|
8 |
58 |
9 |
06/95 |
FD |
FD with epitheliosis, adenosis |
R/P correlation; MR imaging follow-up (4
y) |
Yes (b) |
|
9 |
60 |
10 |
04/98 |
FA |
Focal adenosis |
R/P correlation; MR imaging follow-up (27
mo) |
Yes (b) |
|
10 |
43 |
11 |
07/00 |
FA |
FD |
Secondary excisional biopsy |
Yes (a) |
|
11 |
40 |
12 |
05/00 |
FD or UBO |
Normal breast tissue |
R/P correlation |
No |
|
12 |
33 |
13 |
03/00 |
FD |
Normal breast tissue with adenosis |
R/P correlation; MR imaging follow-up (6
mo) |
No |
| |
|
14 |
|
FD |
Normal breast tissue with adenosis |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
13 |
40 |
15 |
12/99 |
FA |
FA |
R/P correlation; MR imaging follow-up (6 mo) |
Yes (c) |
| |
|
16 |
12/99 |
FD |
Normal breast tissue |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
14 |
43 |
17 |
03/00 |
FD or UBO |
Normal breast parenchyma without
atypias |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
15 |
48 |
18 |
06/00 |
FD or UBO |
Normal breast tissue |
R/P correlation |
No |
|
16 |
42 |
19 |
04/00 |
FD |
FD |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
Patients with lesions rated as
"equivocal" |
|
17 |
42 |
20 |
04/00 |
FA or IBC |
Typical FA |
R/P correlation; MR imaging follow-up (6
mo) |
Yes (c) |
|
18 |
51 |
21 |
01/00 |
FD or DCIS |
FA |
Secondary excisional biopsy; MR imaging
follow-up (6 mo) |
Yes (a) |
| |
|
22 |
01/00 |
FD or DCIS |
FD with adenosis |
Secondary excisional biopsy; MR imaging
follow-up (6 mo) |
Yes (a) |
|
19 |
47 |
23 |
11/98 |
FD or IBC |
FD |
MR imaging follow-up (20 mo); excisional
biopsy in 7/00 |
Yes (a) |
|
20 |
55 |
24 |
09/99 |
FD or IBC |
FD with adenosis and focal mastitis |
R/P correlation; MR imaging follow-up (12
mo) |
No |
|
21 |
46 |
25 |
06/00 |
FA or IBC |
FA |
R/P correlation |
Yes (c) |
|
22 |
47 |
26 |
02/99 |
IBC or FD |
FD with adenosis |
Secondary excisional biopsy; MR imaging
follow-up (6 mo) |
Yes (a) |
| |
|
27 |
02/99 |
IBC or FD |
Adenosis, epitheliosis, no atpyias |
Secondary excisional biopsy; MR imaging
follow-up (6 mo) |
Yes (a) |
|
23 |
40 |
28 |
06/99 |
DCIS or FD |
FD |
Secondary excisional biopsy |
Yes (a) |
|
24 |
29 |
29 |
04/00 |
FA or IBC |
Typical FA |
R/P correlation; MR imaging follow-up (6
mo) |
Yes (c) |
|
25 |
47 |
30 |
11/98 |
FA or IBC |
Typical FA |
R/P correlation; MR imaging follow-up (18
mo) |
Yes (c) |
|
26 |
36 |
31 |
04/00 |
FA or IBC |
Typical FA |
R/P correlation; MR imaging follow-up (6
mo) |
Yes (c) |
| |
|
32 |
04/00 |
FA or DCIS |
Adenosis |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
27 |
34 |
33 |
03/98 |
FA or IBC |
Adenosis |
R/P correlation; MR imaging follow-up (28
mo) |
Yes (b) |
|
28 |
45 |
34 |
02/97 |
FD or IBC |
FD, no atypias |
MR imaging follow-up (12 moths); death due
to bronchial carcinoma; no evidence of breast cancer |
No |
|
29 |
42 |
35 |
11/96 |
FD or DCIS |
FD with epitheliosis |
R/P correlation; MR imaging follow-up (3
y) |
Yes (b) |
|
30 |
53 |
36 |
11/98 |
FA or IBC |
Lymph node hyperplasia |
R/P correlation; MR imaging follow-up (18
mo) |
Yes (c) |
|
31 |
34 |
37 |
05/97 |
FA or IBC |
Adenosis |
MR imaging follow-up (24 mo) |
Yes (b) |
|
32 |
46 |
38 |
03/00 |
FD or DCIS |
FD with adenosis |
R/P correlation; MR imaging follow-up (4
mo) |
No |
|
33 |
41 |
39 |
06/00 |
FA or IBC |
FD, no atypias |
Secondary excisional biopsy |
Yes (a) |
|
34 |
46 |
40 |
04/00 |
FD or DCIS |
Intraductal epithelial proliferations
without atypias |
R/P correlation; MR imaging follow-up (6
mo) |
No |
|
35 |
59 |
41 |
06/97 |
FA or IBC |
FA |
R/P correlation; MR imaging follow-up (18
mo) |
Yes (c) |
|
36 |
63 |
42 |
05/00 |
FA or IBC |
FA |
R/P correlation |
Yes (c) |
|
Patients with lesions rated as
"probably malignant" |
|
37 |
48 |
43 |
05/00 |
IBC |
Mixed ductal lobular IBC |
Excisional biopsy |
Yes (a) |
| |
|
44 |
05/00 |
IBC |
Same as lesion 43 |
Excisional biopsy |
Yes (a) |
|
38 |
36 |
45 |
02/00 |
IBC |
Lobular IBC |
Excisional biopsy |
Yes (a) |
|
39 |
65 |
46 |
09/96 |
IBC |
Mucinous IBC |
Excisional biopsy |
Yes (a) |
|
40 |
35 |
47 |
03/98 |
IBC |
Ductal IBC |
Excisional biopsy |
Yes (a) |
|
41 |
47 |
48 (left) |
05/00 |
IBC |
Poorly differentiated IBC |
Mastectomy
|
Yes (a) |
| |
|
49 (left) |
05/00 |
IBC |
Same as lesion 48 |
Mastectomy
|
Yes (a) |
| |
|
50 (right) |
05/00 |
IBC or FA |
Fibro-hyalinized breast tissue |
Follow-up MR imaging (3 mo) |
No |
| |
|
51 (right) |
05/00 |
IBC or FA |
Same as lesion 50 |
Follow-up MR imaging (3 mo) |
No |
|
42 |
29 |
52 |
08/98 |
IBC |
Ductal IBC |
Excisional biopsy; MR imaging follow-up (24
mo) |
Yes (a) |
|
43 |
35 |
53 |
05/00 |
DCIS |
DCIS (high grade) |
Excisional biopsy |
Yes (a) |
|
44 |
54 |
54 (left) |
06/00 |
DCIS |
Sclerosing adenosis, no DCIS |
R/P correlation |
No |
| |
|
55 (right) |
06/00 |
IBC |
Mixed lobular and ductal IBC |
Mastectomy |
Yes (a) |
| |
|
56 (right)* |
06/00 |
IBC |
Radial scar |
Mastectomy |
Yes (a) |
|
45 |
48 |
57 |
04/00 |
IBC |
Fibrosis, organizing hematoma |
Mastectomy |
Yes (a) |
| |
|
58 |
04/00 |
IBC |
Ductal IBC |
Mastectomy |
Yes (a) |
|
46 |
46 |
59 |
03/00 |
IBC |
Diffusely infiltrating ductal breast
cancer |
Mastectomy after neoadjuvant
chemotherapy |
Yes (a) |
|
47 |
63 |
60 |
08/98 |
IBC |
Ductal IBC |
Excisional biopsy |
Yes (a) |
|
48 |
|
61 |
06/98 |
IBC |
Ductal IBC |
Excisional biopsy |
Yes (a) |
|
49 |
59 |
62 |
10/98 |
IBC |
Poorly differentiated IBC |
Excisional biopsy |
Yes (a) |
|
50 |
42 |
63 |
08/96 |
IBC |
Crushed specimen; no histologic evaluation
possible |
Excisional biopsy§ |
No |
|
51 |
61 |
64 (left)* |
08/00 |
IBC |
Ductal IBC |
Mastectomy |
Yes (a) |
| |
|
65 (left) |
08/00 |
DCIS |
DCIS |
Mastectomy |
Yes (a) |
| |
|
66 (right)* |
08/00 |
IBC |
IBC with different histology than in lesion
64 |
Mastectomy |
Yes (a) |
| |
|
67 (right) |
08/00 |
DCIS |
FD with adenosis, no atypias |
Mastectomy |
Yes (a) |
|
52 |
64 |
68 |
07/00 |
DCIS |
DCIS |
Excisional biopsy |
Yes (a) |
| |
|
69 |
07/00 |
DCIS |
DCIS |
Excisional biopsy |
Yes (a) |
|
53 |
|
70 |
05/99 |
IBC |
Ductal IBC with intraductal component |
Mastectomy |
Yes (a) |
|
54 |
43 |
71 |
04/00 |
IBC or DCIS |
Perifocal fibrosis and inflammatory
reaction, no breast cancer |
Excisional biopsy |
Yes (a) |
| |
|
72 |
04/00 |
IBC |
Poorly differentiated breast cancer |
Excisional biopsy |
Yes (a) |
|
55 |
70 |
73 |
02/96 |
IBC |
Ductal IBC |
Excisional biopsy |
Yes (a) |
|
56 |
59 |
74 |
10/97 |
IBC |
Ductal IBC |
Excisional biopsy |
Yes (a) |
|
57 |
48 |
75 |
08/00 |
IBC |
Mixed lobular and ductal IBC |
Excisional biopsy |
Yes (a) |
| |
|
76 |
08/00 |
IBC |
Proliferative dysplasia, no atypias |
Excisional biopsy |
Yes (a) |
|
58 |
53 |
77 |
03/00 |
IBC |
Ductal IBC |
Excisional biopsy |
Yes (a) |
|
59 |
60 |
78 |
06/00 |
IBC or DCIS |
DCIS |
Excisional biopsy |
Yes (a) |
|
| Note.—DCIS = ductal
carcinoma in situ, FA = fibroadenoma, FD = fibrocystic disease, IBC = invasive breast cancer, LCIS = lobular carcinoma in situ, R/P = radiologic-pathologic, UBO = unidentified bright breast object (ie, suspected hormone-induced enhancement).
|
| *Indicates a mammographically visible index lesion in patients with multicentric breast cancer.
|
|
This column indicates whether the core biopsy diagnoses were considered sufficiently validated to be included in the calculation of diagnostic accuracy of core biopsy. Sufficient validation was obtained with (a) excisional biopsy or (b) a follow-up MR imaging interval of 24 months or more or by (c) an unambigious R/P correlation.
|
|
In this patient, excisional biopsy confirmed radial scar, but the lesion was surrounded by ductal IBC.
|
|
§Excisional biopsy revealed ductal IBC. |
